1. STRIDE trial evaluated semaglutide in individuals with PAD and type 2 diabetes.
2. Semaglutide group showed a significant improvement in maximum walking distance.
3. Patients receiving semaglutide reported less leg pain and better physical function.
4. Ankle-brachial index and additional clinical benefits favored semaglutide.
5. Adverse events occurred in 53% of participants on semaglutide and 46% on placebo.
6. Semaglutide may offer an additional benefit for functional impairment in PAD. 

Source: The Lancet